Tove J. Grönroos

University of Turku — Finland

Biochemistry, Genetics and Molecular Biology · Life Sciences

31h-index3.6kcitations140works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(32), Medical Imaging Techniques and Applications(31), Cancer-related Molecular Pathways(20), Epigenetics and DNA Methylation(18), PARP inhibition in cancer therapy(17)

Publications140 total

<scp>xCT</scp> as a Predictor for Survival in a Population‐Based Cohort of Head and Neck Squamous Cell Carcinoma
Cancer Medicine·2024· 1 citedOpen Access
Non-invasive quantification of stem cell-derived islet graft size and composition
Diabetologia·2024· 7 citedOpen Access
Evaluation of PET imaging as a tool for detecting neonatal hypoxic-ischemic encephalopathy in a preclinical animal model
Experimental Neurology·2023· 1 citedOpen Access
Small animal PET with spontaneous inhalation of <sup>15</sup>O-labelled oxygen gases: Longitudinal assessment of cerebral oxygen metabolism in a rat model of neonatal hypoxic-ischaemic encephalopathy
Journal of Cerebral Blood Flow & Metabolism·2023· 2 citedOpen Access
Quantifying stem cell derived islet graft volume and composition with [ <sup>18</sup> F]F-DBCO-exendin and [ <sup>18</sup> F]FDOPA positron emission tomography
2023Open Access
TSPO is a potential independent prognostic factor associated with cellular respiration and p16 in head and neck squamous cell carcinoma
Frontiers in Oncology·2023· 4 citedOpen Access
Supplementary Table from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
2023Open Access
Data from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
2023Open Access
Supplementary Figure from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
2023Open Access
Data from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
2023Open Access
Supplementary Table from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
2023Open Access
Supplementary Figure from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
2023Open Access
Supplementary Data from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
2023Open Access
Supplementary Table from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
2023Open Access
Supplementary Figure from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
2023Open Access
Supplementary Figure from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
2023Open Access
Supplementary Figure from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
2023Open Access
Supplementary Figure from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
2023Open Access
Supplementary Data from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
2023Open Access
Supplementary Table from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Olof Solin(18), Merja Haaparanta‐Solin(18), Heikki Minn(13), Olli Eskola(13), Sarita Forsbäck(13), Pirjo Nuutila(12), Vesa Oikonen(9), Juhani Knuuti(9), Päivi Marjamäki(9), Jörgen Bergman(8), Kaisa Lehtiö(7), Pertti Lehikoinen(7), Tapio Viljanen(5), Anne Roivainen(4), Pauliina Kronqvist(4), Teemu Takala(4), Patricia Iozzo(4), Gaber Komar(3), Reidar Grénman(3), Eija Sutinen(3)